Or perhaps he limited shareholders to 1 question b
Post# of 30040
Posted On: 02/25/2015 7:05:59 PM
Re: Daveludlow #17220
Or perhaps he limited shareholders to 1 question because of the ridiculous shareholder questions asked in the Sept 2014 Business Update Call, including:
1. If a RS isn't necessary to uplist, then we assume LymPro and Eltoprazine are up for discussion as being sold... you don't have to comment on whether they have been sold to one company or another, but could you address if this is a consideration?
2. When would you expect the company to report a profit? That would include anything... the sale of the diagnostic unit, the sale of LymPro... anything.
What serious investor would ask such questions and waste Gerald's time, knowing there is no way he could answer.
1. If a RS isn't necessary to uplist, then we assume LymPro and Eltoprazine are up for discussion as being sold... you don't have to comment on whether they have been sold to one company or another, but could you address if this is a consideration?
2. When would you expect the company to report a profit? That would include anything... the sale of the diagnostic unit, the sale of LymPro... anything.
What serious investor would ask such questions and waste Gerald's time, knowing there is no way he could answer.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼